Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Takeda and HUTCHMED have announced that the U.S. Food and Drug Administration (“FDA”) has granted […]
Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda
Treventis Corporation, a privately held biotechnology company, announced today that it has entered an option, […]
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Arrowhead Pharmaceuticals today announced that the first patient has been dosed in Takeda’s Phase 3 […]
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda has announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 […]
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib
Takeda has today announced that it has entered into an exclusive licensing agreement with HUTCHMED […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more